Ruixiang Ge

Ruixiang Ge

Auto-generated profile, based on publicly available information

Ruixiang Ge

The Translational Research Institute for Neurological Disorders of Wannan Medical College, Department of Neurosurgery, the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Risk Management and Healthcare Policy
Verified
Journal Article
Open access
PDF file
JSJun Shen
Jun Shen
XSXuefei Shao
Xuefei Shao
RGRuixiang Ge
Ruixiang Ge
GDGuangfu Di
Guangfu Di
XJXiaoChun Jiang
XiaoChun Jiang
Purpose: Postoperative rebleeding (PRB) is one of the most severe complications after hematoma evacuation of spontaneous intracerebral hemorrhage (ICH). PRB has been proven to be an independent risk factor for poor prognosis. Previous studies have shown that spot sign and blend sign are independent risk factors for PRB of spontaneous ICH. However, the risk factors for PRB of spontaneous cerebellar hemorrhage (SCH) have not been elucidated. The aim of the present study was to investigate the possible risk factors for PRB and short-term prognosis of patients with SCH. Patients and Methods: This study identified 62 patients with SCH who underwent hematoma evacuation in our department. Risk factors for PRB and short-term prognosis were identified by a univariable logistic regression model, and predictors with a P value of less than 0.05 were included in the multivariable logistic regression model to identify independent predictors. A receiver operating characteristic (ROC) curve was created to test the sensitivity and specificity of independent risk factors. Results: Hematoma volume was the only independent predictor of PRB (OR=15.14, 95% CI=1.08– 213.1, P=0.044). The sensitivity and specificity of hematoma volume to PRB were 63.6% and 89.7%, respectively, and the cutoff value of hematoma volume was > 29.3 mL. GCS score ≤ 8 (OR=5.131, 95% CI=1.030– 25.554, P=0.046) and PRB (OR=13.17, 95% CI=1.316– 131.798, P=0.028) were independent risk factors for poor prognosis of patients with SCH. The sensitivity and specificity of the GCS score to poor prognosis were 66.7% and 86.2%, respectively. The sensitivity and specificity of the PRB to poor prognosis were 36.4% and 96.6%, respectively. Conclusion: Hematoma volume is likely to be a strong predictor of PRB among patients with SCH. GCS scores ≤ 8 on arrival and PRB were significant predictors of short-term poor outcome.

5 December 2022 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
RGRuixiang Ge
Ruixiang Ge
CWChenci Wang
Chenci Wang
JLJiangang Liu
Jiangang Liu
HJHaibo Jiang
Haibo Jiang
XJXiaoChun Jiang
XiaoChun Jiang
ZLZhuohao Liu
Zhuohao Liu
Our previous study illustrated that nuclear factor IX (NFIX) promotes glioblastoma (GBM) progression by inducing migration and proliferation of GBM cells. However, the underlying mechanism of how NFIX regulates GBM cell proliferation remains obscure. In this study, we uncovered that Go-Ichi-Ni-San 1 (GINS1) is upregulated and positively correlated with NFIX in human GBM specimen. NFIX silencing downregulates the expression of GINS1, which is pivotal for cell-cycle progression and proliferation of GBM cells. Replenishment of GINS1 largely rescues the NFIX-null effect on GBM cell proliferation. Mechanistic investigation revealed that NFIX transcriptionally actives GINS1 expression by directly binding to promoter region (-1779 to -1793bp) of the GINS1 gene. Furthermore, knockdown of NFIX sensitizes GBM cells to DNA damage-inducing agents including doxorubicin and temozolomide, in a GINS1-dependent manner. Implications: Our study highlights that targeting NFIX–GINS1 axis could be a novel and potential therapeutic approach for GBM treatment.

3 April 2023
Verified
Other
Open access
RGRuixiang Ge
Ruixiang Ge
CWChenci Wang
Chenci Wang
JLJiangang Liu
Jiangang Liu
HJHaibo Jiang
Haibo Jiang
XJXiaoChun Jiang
XiaoChun Jiang
ZLZhuohao Liu
Zhuohao Liu
S1. Full images of immunoblotting. S2. NFIX knockdown has no effect on p53 and p21 expression. S3. Knockdown of GINS1 by shRNAs in U87 cells. S4. Knockdown of GINS1 represses proliferation of GL261 cells S5. GINS1 rescues the delayed growth of NFIX-null GL261 tumor. S6. NFIX directly up-regulated GINS1 gene by occupying its promoter

27 November 2025
Verified
Other
Open access
PDF file
RGRuixiang Ge
Ruixiang Ge
CWChenci Wang
Chenci Wang
JLJiangang Liu
Jiangang Liu
HJHaibo Jiang
Haibo Jiang
XJXiaoChun Jiang
XiaoChun Jiang
ZLZhuohao Liu
Zhuohao Liu
Table S1. Primer sequences for mRNA expression analysis. Table S2. Sequences of shRNA. Table S3. Antibodies for immunoblotting.

3 April 2023
Verified
Other
Open access
RGRuixiang Ge
Ruixiang Ge
CWChenci Wang
Chenci Wang
JLJiangang Liu
Jiangang Liu
HJHaibo Jiang
Haibo Jiang
XJXiaoChun Jiang
XiaoChun Jiang
ZLZhuohao Liu
Zhuohao Liu
Table S1. Primer sequences for mRNA expression analysis. Table S2. Sequences of shRNA. Table S3. Antibodies for immunoblotting.

3 April 2023
Verified
Other
Open access
RGRuixiang Ge
Ruixiang Ge
CWChenci Wang
Chenci Wang
JLJiangang Liu
Jiangang Liu
HJHaibo Jiang
Haibo Jiang
XJXiaoChun Jiang
XiaoChun Jiang
ZLZhuohao Liu
Zhuohao Liu
Our previous study illustrated that nuclear factor IX (NFIX) promotes glioblastoma (GBM) progression by inducing migration and proliferation of GBM cells. However, the underlying mechanism of how NFIX regulates GBM cell proliferation remains obscure. In this study, we uncovered that Go-Ichi-Ni-San 1 (GINS1) is upregulated and positively correlated with NFIX in human GBM specimen. NFIX silencing downregulates the expression of GINS1, which is pivotal for cell-cycle progression and proliferation of GBM cells. Replenishment of GINS1 largely rescues the NFIX-null effect on GBM cell proliferation. Mechanistic investigation revealed that NFIX transcriptionally actives GINS1 expression by directly binding to promoter region (-1779 to -1793bp) of the GINS1 gene. Furthermore, knockdown of NFIX sensitizes GBM cells to DNA damage-inducing agents including doxorubicin and temozolomide, in a GINS1-dependent manner.Implications:Our study highlights that targeting NFIX–GINS1 axis could be a novel and potential therapeutic approach for GBM treatment.